News

Agenus price target lowered to $8 from $11 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Agenus (AGEN) to $8 from $11 and keeps a Buy rating on the shares. The firm ...
Novavax shares soar after FDA request raises hope for COVID vaccine approval
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
Novavax's stock surges on 'good news' from Food and Drug Administration
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
FDA asks Novavax for post-approval data on COVID vaccine, raising hopes for green light
The company is seeking to convert the vaccine’s emergency use authorization received in 2022 into a full approval that would ...
U.S. News & World Report5d
Novavax Shares Soar After FDA Request Raises Hope for COVID Vaccine Approval
"I think the odds for approval went up quite a bit," B Riley analyst Mayank Mamtani said in an interview, adding that Wednesday's request from the FDA gave investors clarity on the path to ...
Business Insider27d
Harrow price target lowered to $65 from $69 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following the Q4 report. The firm believes the ...
FDA asks Novavax for post-approval data on COVID vaccine, shares soar
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...